Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Allurion Technologies, Inc. (ALUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit -24.63% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.74M USD | Price to earnings Ratio - | 1Y Target Price 10.62 |
Price to earnings Ratio - | 1Y Target Price 10.62 | ||
Volume (30-day avg) 2881779 | Beta -0.63 | 52 Weeks Range 2.15 - 98.75 | Updated Date 04/2/2025 |
52 Weeks Range 2.15 - 98.75 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-03-26 | When - | Estimate -30.2475 | Actual -6.9914 |
Profitability
Profit Margin -81.43% | Operating Margin (TTM) -370.51% |
Management Effectiveness
Return on Assets (TTM) -54.05% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42283347 | Price to Sales(TTM) 0.61 |
Enterprise Value 42283347 | Price to Sales(TTM) 0.61 | ||
Enterprise Value to Revenue 1.32 | Enterprise Value to EBITDA -2.15 | Shares Outstanding 5963550 | Shares Floating 4792010 |
Shares Outstanding 5963550 | Shares Floating 4792010 | ||
Percent Insiders 14.47 | Percent Institutions 23.24 |
Analyst Ratings
Rating 4.25 | Target Price 28.67 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Allurion Technologies, Inc.
Company Overview
History and Background
Allurion Technologies, Inc. was founded in 2009 with the goal of creating innovative solutions for weight loss. The company developed the Allurion Program, a non-surgical weight loss solution featuring the Allurion Balloon. The company went public in August 2023 via a SPAC merger.
Core Business Areas
- Weight Loss Program: Allurion's primary business is the Allurion Program, a comprehensive weight loss solution centered around their swallowable gastric balloon. This program includes nutritional support and lifestyle coaching.
Leadership and Structure
The leadership team includes Shantanu Gaur (CEO) and other key executives in finance, operations, and marketing. The company operates with a focus on research and development, sales and marketing, and global expansion.
Top Products and Market Share
Key Offerings
- Allurion Program: The Allurion Program involves a swallowable gastric balloon, a 16-week weight-loss program, and connected scale and app. The balloon is designed to promote satiety and reduce food intake. Competitors include Apollo Endosurgery (APEN), Reshape Lifesciences (RSLS), and other surgical and non-surgical weight loss solutions.
Market Dynamics
Industry Overview
The weight loss industry is driven by increasing obesity rates and growing demand for effective solutions. This market is segmented by diet, surgical interventions, and non-surgical medical devices.
Positioning
Allurion positions itself as a leader in non-surgical, technology-driven weight loss solutions. Their competitive advantage lies in the ease of use and minimal invasiveness of their swallowable balloon and integrated support program.
Total Addressable Market (TAM)
The global weight management market is estimated to be worth hundreds of billions of dollars. Allurion is positioned to capture a portion of this market through its focus on non-surgical interventions.
Upturn SWOT Analysis
Strengths
- Non-surgical approach
- Integrated program
- Technology-driven solution
- Global presence
Weaknesses
- Higher cost compared to diet and exercise
- Potential for balloon intolerance
- Reliance on third-party manufacturing
- Limited long-term data
Opportunities
- Expanding geographic reach
- Developing new products
- Partnering with healthcare providers
- Increasing consumer awareness
Threats
- Competition from established weight loss companies
- Regulatory changes
- Economic downturns
- Negative publicity
Competitors and Market Share
Key Competitors
- APEN
- RSLS
Competitive Landscape
Allurion's strengths are the non-surgical approach and integrated program. Weaknesses include higher cost and reliance on third-party manufacturing. Competitors may offer lower-cost options or longer-term data.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the recency of the public listing. Prior to the listing, growth can be estimated by reviewing earlier funding rounds and reports.
Future Projections: Future projections are typically based on analyst estimates. Key assumptions include market adoption rates, pricing strategies, and regulatory approvals.
Recent Initiatives: Recent initiatives include expanding into new geographic markets and launching new versions of their program.
Summary
Allurion Technologies presents an interesting investment opportunity within the weight loss market with its non-surgical, technology-driven approach. While the integrated program and expanding global presence are strengths, the higher cost and reliance on third-party manufacturing pose challenges. The company needs to focus on demonstrating long-term efficacy and cost-effectiveness to compete effectively and should be aware of competitive pressures and regulatory changes.
Similar Companies
RSLS
ReShape Lifesciences Inc
RSLS
ReShape Lifesciences Inc
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Analyst Reports
- SEC Filings (limited)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allurion Technologies, Inc.
Exchange NYSE | Headquaters Natick, MA, United States | ||
IPO Launch date 2023-08-02 | Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Dr. Shantanu K. Gaur M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://www.allurion.com |
Full time employees - | Website https://www.allurion.com | ||
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.